Retatrutide is a triple-receptor agonist research peptide engaging GIP, GLP-1, and glucagon receptors simultaneously. Verifying purity is particularly important for triple agonists because synthesis errors at any of the three receptor-binding domains produce truncated peptides that retain partial activity but skew dose-response curves in research models. The Certificate of Analysis on this page documents both independent third-party HPLC verification by Janoshik Analytical and BodyPharm in-house testing of the production batch.
Janoshik Analytical
Independent third-party laboratory
- Report
- #106564
- Batch
- RET4683
- Purity (HPLC)
- 99.409%
- Sample Received
- 06 Feb 2026
In-House Testing
BodyPharm laboratory
- Report
- #20251011
- Batch
- RET3254
- Purity (HPLC)
- 98.75%
- Concentration
- 14.06 mg/ml
Testing Methodology
Third-Party Verification by Janoshik Analytical
Janoshik report #106564 documents Reverse-Phase HPLC analysis of batch RET4683, sample received on 06 February 2026. Janoshik Analytical operates as an independent verification service and submits results directly to verify.janoshik.com - publicly accessible records that cannot be modified after submission. Reverse-phase HPLC was selected for retatrutide because the peptide hydrophobic backbone and lipophilic side chain produce strong, well-resolved retention on a C18 column, making minor synthesis byproducts easier to distinguish from the target peak.
In-House HPLC Confirmation
Each retatrutide batch is independently re-tested in the BodyPharm laboratory to confirm purity and document concentration in the final pen formulation. Batch RET3254 (in-house report #20251011) measured 98.75% purity at 14.06 mg/ml. The slight purity differential between Janoshik and in-house values reflects normal between-laboratory variation in integration parameters rather than a true purity difference. Concentration is verified by integration against an internal reference standard at the time of fill.
Triple Agonist Identity Verification
Distinguishing retatrutide from related dual-agonist peptides such as tirzepatide requires both purity and identity confirmation. The HPLC retention time on the certificate is matched against a retatrutide reference standard with documented retention behaviour. Mass-based identity confirmation by LC-MS is conducted on representative batches to verify the full triple-agonist sequence is intact and is available on request for institutional research procurement.
What This Result Means for Researchers
Retatrutide research applications include investigation of GIP, GLP-1, and glucagon receptor signalling cross-talk in metabolic biology, body weight regulation models, and hepatic glucose homeostasis studies. Phase 2 clinical trial data published in The New England Journal of Medicine (2023) documented substantial body weight changes in human subjects, but research-grade material is supplied for laboratory study only. Triple agonist purity is a critical experimental variable because the relative GIP/GLP-1/glucagon activity ratio is sensitive to even minor synthesis variation. Researchers comparing retatrutide to single GLP-1 agonists such as semaglutide should reference batch-specific COA data to ensure their material matches the assumed mechanism profile.
Frequently Asked Questions
Related Products
Retatrutide 32 Pen
Retatrutide 32mg pre-filled research pen with HPLC-verified purity at 99.409%.